- Home >
- Institut Curie News >
- ASCO 2026: Circulating biomarkers, biological avatars, innovative imaging, remote monitoring… The Institut Curie at the center of the conference announcements
From May 29 to June 2, 2026 in Chicago (USA), the world cancer community will gather, as it does every year, for the unmissable congress of the American Society of Clinical Oncology (ASCO). With numerous communications, doctors and researchers from Institut Curie will be present to share promising advances aimed at accelerating cancer research through innovative personalized and adaptive medicine approaches.
The challenge of oncology today is no longer only to customize treatment to the diagnosis, but to continuously adapt the therapeutic strategy to the dynamics and the tumor evolution. This year at the ASCO congress, the teams of Institut Curie demonstrate all the promises of this adaptive medicine which, tomorrow, will considerably improve the care of patients, in all its dimensions. These promising prospects reinforce our commitment and our will to transform clinical research into concrete sources of hope for patients.
Professor Steven Le Gouill Director of the Institut Curie Hospital
The 2026 edition at a glance
The main presentations by doctors and researchers from the Institut Curie at ASCO 2026 will focus in particular on:
Breast Cancers
- Long-term benefit of therapeutic adaptation guided by the detection of circulating tumor DNA
- Biological avatars to predict the effectiveness and adapt treatments to each patient
- A new radiotracer to monitor tumor progression and detect relapses?
- A new triple therapy in aggressive metastatic breast cancers (HER2+)
- Therapeutic de-escalation: evaluation of the suppression of chemotherapy for certain patients
- Pregnancy and cancer: the maternal and fetal complications of chemotherapy
Uveal melanoma
A promising new avenue in metastatic melanomas of the eye
Lung cancer
MOOVCARE®: A Remote Monitoring Device Under Study in Lung Cancers
